The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007

Table of Contents

1 Executive Summary

• 1.1 Report Scope
• 1.2 Definitions
  • 1.2.1 Alzheimer' s Disease
  • 1.2.2 Parkinson' s Disease
  • 1.2.3 Multiple Sclerosis
  • 1.2.4 Amyotrophic Lateral Sclerosis
  • 1.2.5 Huntington' s Disease
  • 1.2.6 Neuropathies
• 1.3 Report Methodology
• 1.4 The Market
• 1.5 Market Composition
• 1.6 Competitive Profiles
• 1.7 Factors to Growth

2 The Market

• 2.1 Global Pharmaceutical Market
• 2.2 Global Neurodegenerative Market
• 2.3 Market Size and Growth
• 2.4 Market Composition
• 2.5 US/North American Market
  • 2.5.1 Overview
  • 2.5.2 US Neurodegenerative Market
  • 2.5.3 Canadian Neurodegenerative Market
  • 2.5.4 Regulatory Scenario
• 2.6 European Market
  • 2.6.1 Overview
  • 2.6.2 Regulatory Scenario
• 2.7 Japanese Market
  • 2.7.1 Overview
  • 2.7.2 Japanese Neurodegenerative Market
  • 2.7.3 Regulatory Scenario

3 Market Composition: Alzheimer' s Disease

• 3.1 Overview
• 3.2 Risk Factors
• 3.3 Symptoms
• 3.4 Therapies
• 3.5 Market Size and Growth
• 3.6 Market Composition
• 3.7 By Region
• 3.8 Major Players
• 3.9 Anti-Alzheimer' s Disease Products
  • 3.9.1 AChE inhibitors
  • 3.9.2 NMDA Antagonists
• 3.10 Incidence of Alzheimer' s Disease
• 3.11 In the Pipeline
• 3.12 Looking Ahead
• 3.13 Key Clinical Trials
• 3.14 Key Emerging Therapies
• 3.15 Research and Development Trends

4 Market Composition: Parkinson' s Disease

• 4.1 Overview
• 4.2 Risk Factors
• 4.3 Symptoms
• 4.4 Therapies
• 4.5 Market Size and Growth
• 4.6 Market Composition by Region
• 4.7 Major Players
• 4.8 Anti-Parkinson' s Disease Products
  • 4.8.1 Anticholinergics
  • 4.8.2 COMT Inhibitors
  • 4.8.3 Combination Anti-Parkinson' s Agents
  • 4.8.4 Dopamine Receptor Agonists
  • 4.8.5 Carbidopa Levodopa Preparations
  • 4.8.6 MAO-B inhibitors
  • 4.8.7 Amantadine
• 4.9 Incidence and Prevalence of Parkinson' s Disease
• 4.10 In the Pipeline
• 4.11 Looking Ahead
• 4.12 Key Clinical Trials
• 4.13 Key Emerging Therapies
• 4.14 Key Types of Therapies in Development

5 Market Composition: Multiple Sclerosis

• 5.1 Overview
• 5.2 Risk Factors
• 5.3 Symptoms
• 5.4 Therapies
• 5.5 Market Size and Growth
• 5.6 Market Composition
• 5.7 Major Players
• 5.8 Multiple Sclerosis Products
  • 5.8.1 Avonex
  • 5.8.2 Betaseron
  • 5.8.3 Rebif
  • 5.8.4 Copaxone
  • 5.8.5 Novantrone
  • 5.8.6 Symptomatic Relief
• 5.9 Incidence of Multiple Sclerosis
• 5.10 In the Pipeline
• 5.11 Looking Ahead
• 5.12 Key Emerging Therapies
• 5.13 Key Late-Stage Clinical Therapeutics
• 5.14 Key Clinical Trials

6 Market Composition: Amyotrophic Lateral Sclerosis

• 6.1 Overview
• 6.2 Risk Factors
• 6.3 Symptoms
• 6.4 Therapies
• 6.5 Major Players
• 6.6 Anti-Amyotrophic Lateral Sclerosis Products
• 6.7 Incidence of Anti-Amyotrophic Lateral Sclerosis
• 6.8 In the Pipeline
• 6.9 Key Emerging Therapies
• 6.10 Key Clinical Trials

7 Market Composition: Huntington' s Disease

• 7.1 Overview
• 7.2 Risk Factors
• 7.3 Symptoms
• 7.4 Therapies
• 7.5 Market Size and Growth
• 7.6 Market Composition by Region
• 7.7 Major Players
• 7.8 Anti-Huntington' s Disease Products
  • 7.8.1 Neuroleptics
  • 7.8.2 Benzodiazepines
• 7.9 Incidence of Huntington' s Disease
• 7.10 In the Pipeline
• 7.11 Key Emerging Therapies

8 Neuropathies

• 8.1 Overview
• 8.2 Risk Factors
• 8.3 Symptoms
• 8.4 Therapies
• 8.5 Market Size and Growth
• 8.6 Anti-Neuropathies Products
  • 8.6.1 Anticonvulsants
  • 8.6.2 Antidepressants
  • 8.6.3 Analgesics
  • 8.6.4 Others
• 8.7 Incidence of Neuropathies
• 8.8 In the Pipeline
• 8.9 Looking Ahead
• 8.10 Key Emerging Therapies
• 8.11 Key Clinical Trials

9 Competitive Profiles

• 9.1 Amarin
  • 9.1.1 Product Pipeline
  • 9.1.2 Key Financials
• 9.2 AstraZeneca
  • 9.2.1 Product Portfolio
  • 9.2.2 Product Pipeline
  • 9.2.3 Key Financials
• 9.3 Avanir
  • 9.3.1 Product Portfolio
  • 9.3.2 Product Pipeline
  • 9.3.3 Key Financials
• 9.4 Avigen
  • 9.4.1 Product Pipeline
  • 9.4.2 Key Financials
• 9.5 Biogen Idec
  • 9.5.1 Product Portfolio
  • 9.5.2 Product Pipeline
  • 9.5.3 Key Financials
• 9.6 Boehringer Ingelheim
  • 9.6.1 Product Portfolio
    • 9.6.1.1 Key Financials
• 9.7 Daiichi Sankyo
  • 9.7.1 Product Portfolio
  • 9.7.2 Key Financials
• 9.8 Eisai
  • 9.8.1 Product Portfolio
  • 9.8.2 Product Pipeline
  • 9.8.3 Key Financials
• 9.9 Elan
  • 9.9.1 Product Portfolio
  • 9.9.2 Product Pipeline
  • 9.9.3 Key Financials
• 9.10 Eli Lilly
  • 9.10.1 Product Portfolio
  • 9.10.2 Product Pipeline
  • 9.10.3 Key Financials
• 9.11 Forest Laboratories
  • 9.11.1 Product Portfolio
  • 9.11.2 Product Pipeline
  • 9.11.3 Key Financials
• 9.12 Genzyme
  • 9.12.1 Product Pipeline
  • 9.12.2 Key Financials
• 9.13 GlaxoSmithKline
  • 9.13.1 Product Portfolio
  • 9.13.2 Product Pipeline
  • 9.13.3 Key Financials
• 9.14 Guilford Pharmaceuticals/MGI Pharma
  • 9.14.1 Product Pipeline
  • 9.14.2 Key Financials
• 9.15 IVAX
  • 9.15.1 Product Portfolio
  • 9.15.2 Key Financials
• 9.16 Johnson & Johnson
  • 9.16.1 Product Portfolio
  • 9.16.2 Product Pipeline
  • 9.16.3 Key Financials
• 9.17 Kyowa Hakko Kogyo
  • 9.17.1 Product Portfolio
  • 9.17.2 Product Pipeline
  • 9.17.3 Key Financials
• 9.18 Lundbeck
  • 9.18.1 Product Portfolio
  • 9.18.2 Product Pipeline
  • 9.18.3 Key Financials
• 9.19 Merck KGaa
  • 9.19.1 Product Portfolio
  • 9.19.2 Product Pipeline
  • 9.19.3 Key Financials
• 9.20 Mitsubishi Pharma
  • 9.20.1 Product Portfolio
  • 9.20.2 Product Pipeline
  • 9.20.3 Key Financials
• 9.21 Novartis
  • 9.21.1 Product Portfolio
  • 9.21.2 Product Pipeline
  • 9.21.3 Key Financials
• 9.22 Pain Therapeutics
  • 9.22.1 Product Pipeline
  • 9.22.2 Key Financials
• 9.23 Pfizer
  • 9.23.1 Product Portfolio
  • 9.23.2 Product Pipeline
  • 9.23.3 Key Financials
• 9.24 Prestwick Pharmaceuticals
  • 9.24.1 Product Pipeline
• 9.25 Roche
  • 9.25.1 Product Pipeline
  • 9.25.2 Key Financials
• 9.26 Sanofi-Aventis
  • 9.26.1 Product Portfolio
  • 9.26.2 Product Pipeline
  • 9.26.3 Key Financials
• 9.27 Schering AG
  • 9.27.1 Product Portfolio
  • 9.27.2 Product Pipeline
  • 9.27.3 Key Financials
• 9.28 Shire Plc
  • 9.28.1 Product Portfolio
  • 9.28.2 Product Pipeline
  • 9.28.3 Key Financials
• 9.29 Solvay
  • 9.29.1 Product Portfolio
  • 9.29.2 Product Pipeline
  • 9.29.3 Key Financials
• 9.30 Takeda
  • 9.30.1 Product Pipeline
  • 9.30.2 Key Financials
• 9.31 Teva
  • 9.31.1 Product Portfolio
  • 9.31.2 Product Pipeline
  • 9.31.3 Key Financials
• 9.32 Valeant Pharmaceuticals
  • 9.32.1 Product Portfolio
  • 9.32.2 Product Pipeline
  • 9.32.3 Key Financials
• 9.33 Wyeth
  • 9.33.1 Product Portfolio
  • 9.33.2 Product Pipeline
  • 9.33.3 Key Financials

10 Factors to Growth

• 10.1 Demographic
• 10.2 Healthcare Spends
• 10.3 Disease Conditions
• 10.4 Patent Expiry of Popular Products
• 10.5 New Drug Therapies
• 10.6 Growth of Generics
  • 10.6.1 Key Facts about Generics
  • 10.6.2 Generics in the Future

• Appendix A: Patent Expiries
• Appendix B: Alzheimer' s Disease Clinical Research
• Appendix C: Parkinson' s Disease Clinical Research
• Appendix D: Multiple Sclerosis Clinical Research
• Appendix E: Amyotrophic Lateral Sclerosis Clinical Research
• Appendix F: Huntington' s Disease Clinical Research
• Appendix G: Neuropathies Clinical Research
• Appendix H: Notes on Related Dementias (RD)
• Appendix I: Notes on Parkinsonism

Tables

• Table 2.1 United States Health Insurance Expenditures by Type of Expenditure
• Table 2.2 Visits made to physicians by age group and sex (%)
• Table 2.3 Usage of Prescription Drugs by Type
• Table 2.4 Cholinesterase Inhibitors Expenditure per 1000 Persons Aged 65
• Table 3.1 World Market for Alzheimer' s Disease by Region, 2005 ($)
• Table 3.2 Global Sales (2001 - 2005) - Aricept ($ mn)
• Table 3.3 Global Sales Forecast (2006-2010) - Aricept ($ mn)
• Table 3.4 Global Sales (2001 - 2005) - Exelon ($ mn)
• Table 3.5 Global Sales Forecast (2006-2010) - Exelon ($ mn)
• Table 3.6 Global Sales (2001 - 2005) - Reminyl ($ mn)
• Table 3.7 Global Sales Forecast (2006-2010) - Reminyl ($ mn)
• Table 3.8 Global Sales Forecast (2004-2010) - Namenda/Ebixia ($ mn)
• Table 3.9 Alzheimer' s Disease Incidence
• Table 3.10 Prevalence of Alzheimer' s Disease - (Million)
• Table 3.11 Alzheimer' s Disease Pipeline
• Table 3.12 World Market for Anti-Alzheimer' s Products, 2006-2010 ($ mn)
• Table 4.1 World Market for Parkinson' s Disease by Region, 2005 ($)
• Table 4.2 Global Sales Forecast - Comtan ($ mn)
• Table 4.3 Global Sales Forecast - Tasmar ($mn)
• Table 4.4 Global Sales Forecast - Stalevo ($ mn)
• Table 4.5 Global Sales Forecast - Mirapex/Sifrol ($mn)
• Table 4.6 Global Sales - Requip ($ mn)
• Table 4.7 Global Sales Forecast - Requip ($ mn)
• Table 4.8 Prevalence of Parkinson' s Disease (mn)
• Table 4.9 Parkinson' s Disease Pipeline
• Table 4.10 World Market for Anti-Parkinson' s Products, 2006-2010 ($ mn)
• Table 4.11 Available and Emerging Drugs for Parkinson' s Disease
• Table 5.1 Global Sales - Avonex ($ mn)
• Table 5.2 Global Sales Forecast - Avonex ($ mn)
• Table 5.3 Global Sales - Betaseron ($ mn)
• Table 5.4 Global Sales Forecast - Betaseron ($ mn)
• Table 5.5 Global Sales - Rebif ($ mn)
• Table 5.6 Global Sales forecast - Rebif ($ mn)
• Table 5.7 Global Sales - Copaxone ($ mn)
• Table 5.8 Global Sales Forecast - Copaxone ($ mn)
• Table 5.9 Multiple Sclerosis Pipeline
• Table 5.10 Forecast of Multiple Sclerosis Drug Market, 2006-2010 ($ mn)
• Table 6.1 Amyotrophic Lateral Sclerosis Pipeline
• Table 7.1 Global Sales Forecast - Risperdal ($ mn)
• Table 7.2 Huntington' s Disease Pipeline
• Table 8.1 Global Sales - Tegretol ($ mn)
• Table 8.2 Global Sales Forecast - Tegretol ($ mn)
• Table 8.3 Global Sales - Neurontin ($ mn)
• Table 8.4 Global Sales Forecast - Neurontin ($ mn)
• Table 8.5 Global Sales Forecast - Cymbalta ($ mn)
• Table 8.6 Global Sales Forecast - Lyrica ($ mn)
• Table 8.7 Neuropathies Pipeline
• Table 8.8 Global Neuropathic Pain Market ($ mn)
• Table 9.1 Companies Active in Neurodegenerative Research, by Condition
• Table 10.1 Major US Patent Expiries 2005-2007
• Table 10.2 World Market for Neurodegenerative Drug, 2006-2010 ($ mn)

Graphs

• Graph 2.1 Global Pharmaceutical Sales 2001-2005
• Graph 2.2 Global Pharmaceutical Sales by Region, 2005**
• Graph 2.3 Leading Products by Global Pharmaceutical Sales, 2005**
• Graph 2.4 Leading Therapy Classes by Global Pharmaceutical Sales, 2005**
• Graph 2.5 Number of Parkinson Drug Prescriptions Dispensed
• Graph 2.6 Recommended Drug Therapies for Parkinson' s Disease
• Graph 3.1 World Market for Alzheimer' s Disease by Region, 2005 (%)
• Graph 3.2 Alzheimer' s Disease Prevalence
• Graph 4.1 World Market for Parkinson' s Disease by Region, 2005 (%)
• Graph 5.1 Market Share of Leading Multiple Sclerosis Therapies, 2005
• Graph 8.1 Top Causes of Pain
• Graph 10.1 Percentage Increase in Age 60 and Over by Region, 2000-2050
• Graph 10.2 World Aging Trends
• Graph 10.3 Health Spending in Organization for Economic Co-operation and Development (OECD) Countries as % of GDP, 2003
• Graph 10.4 Government Expenditure on Health
• Graph 10.5 U.S. Growth of Generics, 1984-2005
• Graph 10.6 U.S. Generics vs. Brand-Name Pharmaceuticals Sales, 2005
• Graph 10.7 Generic Drug Sales in U.S. (projected)